New Drug for Chronic Myeloid Leukemia Might Stimulate the Market.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33109738.
- Also identified by DOI 10.1158/1078-0432.CCR-20-3684.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability.<i>See related article by Zhang et al., p. 70</i>.
Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Pharmaceutical Preparations